Long-term tolerability of ticagrelor for the secondary prevention of major adverse cardiovascular events: A secondary analysis of the PEGASUS-TIMI 54 trial

JAMA Cardiology

Volumn 1, Issue 4, 2016, Pages 425-432

  Bonaca, Marc P ^a   Bhatt, Deepak L ^a   Oude Ophuis, Ton ^b   Gabriel Steg, P ^c,d   Storey, Robert ^e   Cohen, Marc ^f   Kuder, Julia ^a   Im, Kyungah ^a   Magnani, Giulia ^a   Budaj, Andrzej ^g   Theroux, Pierre ^h   Hamm, Christian ^i,j   Špinar, Jindřich ^k   Kiss, Robert G ^l   Dalby, Anthony J ^m   Medina, Felix A ⁿ   Kontny, Frederic ^o   Aylward, Philip E ^p   Jensen, Eva C ^q   Held, Peter ^q   Braunwald, Eugene ^a   Sabatine, Marc S ^a   more..

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c BICHAT HOSPITAL   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

^f RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^g GROCHOWSKI HOSPITAL   (Poland)

^h MONTREAL HEART INSTITUTE   (Canada)

ⁱ KERCKHOFF HEART CENTER   (Germany)

^j JUSTUS LIEBIG UNIVERSITY   (Germany)

^k UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^l Military Hospital National Health Center   (Hungary)

^m MILPARK HOSPITAL   (South Africa)

ⁿ HOSPITAL NACIONAL CAYETANO HEREDIA   (Peru)

^o STAVANGER UNIVERSITY HOSPITAL   (Norway)

^p FLINDERS UNIVERSITY   (Australia)

^q ASTRAZENECA R AND D   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO; TICAGRELOR; ADENOSINE; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ARTICLE; BLEEDING; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EXPLORATORY RESEARCH; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MAJOR ADVERSE CARDIAC EVENT; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; SENSITIVITY ANALYSIS; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; QUALITY OF LIFE;

ADENOSINE; DYSPNEA; HEMORRHAGE; HUMANS; MYOCARDIAL INFARCTION; PURINERGIC P2Y RECEPTOR ANTAGONISTS; QUALITY OF LIFE; SECONDARY PREVENTION; STROKE;

EID: 84997308049     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2016.1017     Document Type: Article

References (10)

1. Bonaca MP, Bhatt DL, Cohen M, et al; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with priormyocardial infarction. N Engl J Med. 2015;372(19):1791-1800.
2. Bonaca MP, Bhatt DL, Braunwald E, et al. Design and rationale for the Prevention of Cardiovascular Events in PatientsWith Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis inMyocardial Infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J. 2014;167(4): 437-444.e5.
3. Wallentin L, Becker RC, Budaj A, et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-1057.
4. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27(9): 1038-1047.
5. Kolandaivelu K, Leiden BB, O'Gara PT, Bhatt DL. Non-adherence to cardiovascular medications. Eur Heart J. 2014;35(46):3267-3276.
6. Collet JP, Montalescot G, Steg PG, et al. Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial. Arch Cardiovasc Dis. 2009;102(6-7):485-496.
7. Gurbel PA, Erlinge D, Ohman EM, et al; TRILOGY ACS Platelet Function Substudy Investigators. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: The TRILOGY ACS platelet function substudy. JAMA. 2012;308(17): 1785-1794.
8. PriceMJ. Measured drug effect and cardiovascular outcomes in patients receiving platelet P2Y12 receptor antagonists: Clarifying the time and place for intensive inhibition. JAMA. 2012; 308(17):1806-1808.
9. Mauri L, Kereiakes DJ, Yeh RW, et al; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155-2166.
10. Udell JA, Bonaca MP, Collet JP, et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previousmyocardial infarction: A collaborative meta-analysis of randomized trials. Eur Heart J. 2016;37(4):390-399.